Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury
- 1 July 2002
- journal article
- research article
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 40 (1), 90-103
- https://doi.org/10.1053/ajkd.2002.33917
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysisKidney International, 2001
- Suspected iron dextran-related adverse drug events in hemodialysis patientsAmerican Journal of Kidney Diseases, 2001
- Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron–saccharate administrationNephrology Dialysis Transplantation, 2000
- The Comparative Safety of Intravenous Iron Dextran, Iron Saccharate, and Sodium Ferric GluconateSeminars in Dialysis, 2000
- Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapyNephrology Dialysis Transplantation, 1999
- Comparative Look at Intravenous Iron Agents: Pharmacology, Efficacy, and Safety of Iron Dextran, Iron Saccharate, and Ferric GluconateSeminars in Dialysis, 1999
- Atherosclerosis — An Inflammatory DiseaseThe New England Journal of Medicine, 1999
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinThe New England Journal of Medicine, 1998
- Cellular and molecular studies of atherogenesisAtherosclerosis, 1997
- Lipid peroxidation: its mechanism, measurement, and significanceThe American Journal of Clinical Nutrition, 1993